MK-1084 (KRAS G12C inhibitor) plus cetuximab drives 50% responses in advanced colorectal cancer
- Trial ID
- NCT05067283 on ClinicalTrials.gov
- Cancer type
- Colorectal Cancer
- Published in
- New in Oncology - May 29, 2025
Phase 1 KANDLELIT-001 (NCT05067283) enrolled pre-treated KRAS G12C-mut CRC: 53 received MK-1084 monotherapy (ORR 36%), 34 got MK-1084 + cetuximab after ≥2 prior lines (ORR 50%), and 20 front-line patients received MK-1084 + cetuximab + mFOLFOX6 (ORR 14%); all responses were partial. Grade ≥3 treatment-related AEs occurred in 9%, 18%, and 25%, respectively (rash/dermatitis and nausea most common), with one DLT (febrile neutropenia) and no treatment-related deaths.
Take home
Early activity suggests MK-1084 could outshine first-generation KRAS G12C regimens in CRC, but durability—and whether dermatologic toxicity stays manageable—are open questions.
Source: Read the original publication
More on NCT05067283
-
Trial result · Jun 7, 2025
MK-1084 (KRAS G12C inhibitor) + pembrolizumab drives 74% ORR and 25-month PFS in first-line metastatic NSCLC
More in colorectal cancer
-
New trial · Oct 15, 2026 · NCT07750158
Phase 3 STELLAR-316 tests zanzalintinib with or without pembrolizumab for ctDNA-positive, scan-negative colorectal cancer -
New trial · Oct 15, 2026 · NCT07842965
Phase 1/1b CHAMP adds CCR5 blockade with leronlimab to surgery, hepatic arterial floxuridine, and systemic therapy for colorectal liver metastases -
New trial · Oct 15, 2026 · NCT07551596
Phase 2 COMBAT tests botensilimab plus balstilimab for ctDNA-positive molecular residual disease in MSS colorectal cancer -
New trial · Oct 8, 2026 · NCT07811193
Phase 2 VVD-133214 WRN helicase covalent inhibitor + pembrolizumab (PD-1 antibody) in MSI/dMMR CRC -
New trial · Oct 8, 2026 · NCT07808151
Phase 2 porustobart CTLA-4 antibody + pembrolizumab PD-1 antibody in resectable MSS colon cancer